Pulmonx stock.

Dec 1, 2023 · The stock of Pulmonx Corp (LUNG) has seen a -2.31% decrease in the past week, with a 18.89% gain in the past month, and a 5.63% flourish in the past quarter. The volatility ratio for the week is 5.66%, and the volatility levels for the past 30 days are at 5.40% for LUNG. The simple […] Pulmonx shares have a market-typical stock price level. While they show above average growth, they are riskily financed, and are poor value. We recommend evaluating whether the future of the company Pulmonx is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the …Pulmonx also continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.Nov 13, 2023 · Pulmonx Corp Stock Price History. Pulmonx Corp’s price is currently up 13.99% so far this month. During the month of November, Pulmonx Corp’s stock price has reached a high of $10.10 and a low of $8.60. Over the last year, Pulmonx Corp has hit prices as high as $14.28 and as low as $5.13. Year to date, Pulmonx Corp’s stock is down 68.76%.

Pulmonx Corp’s Stock Price as of Market Close. As of March 10, 2023, 4:00 PM CST, Pulmonx Corp’s stock price was $10.74. Pulmonx Corp is down 5.79% from its previous closing price of $11.40. During the last market session, Pulmonx Corp’s stock traded between $11.23 and $11.93. Currently, there are 37.38 million shares of Pulmonx Corp ...Nov 24, 2023 · Pulmonx Corp Stock Price History. Pulmonx Corp’s price is currently up 25.71% so far this month. During the month of November, Pulmonx Corp’s stock price has reached a high of $11.43 and a low of $8.60. Over the last year, Pulmonx Corp has hit prices as high as $14.28 and as low as $5.28. Year to date, Pulmonx Corp’s stock is down 65.54%. Nov 29, 2023 · 7 equities research analysts have issued twelve-month price targets for Pulmonx's shares. Their LUNG share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.29 in the next year. This suggests a possible upside of 20.2% from the stock's current price.

Geoffrey Beran Rose, Insider at Pulmonx (NASDAQ:LUNG), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange ...

October 25, 2023. $8.40. 266,866. 1:1. $8.58. $8.73. $8.27. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.In the last ninety days, Geoffrey Beran Rose has sold $22,436.80 in shares of Pulmonx stock. Most recently, Geoffrey Beran Rose sold 1,184 shares of the business's stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $10.60, for a transaction totalling $12,550.40.Glendon E. French III Sells 6,533 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock. Pulmonx Co. (NASDAQ:LUNG – Get Rating) CEO Glendon E. French III sold 6,533 shares of Pulmonx stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $11.48, ...Notably, the market responded positively to LUNG stock, sending it up 56% since the Jan. opener. ... However, Pulmonx is an aspirational entity, incurring a three-year revenue growth rate of 2.8% ...

Pulmonx also continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.

Pulmonx continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based ...

Pulmonx General Information. Description. Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform.Glendon E. French, III has not been actively trading shares of Pulmonx within the last three months. Most recently, Glendon E. French III sold 6,527 shares of the business's stock in a transaction on Friday, September 1st. The shares were sold at an average price of $10.01, for a transaction totalling $65,335.27.Canaccord Genuity Group decreased their price objective on shares of Pulmonx from $20.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, October 31st.Nov 21, 2023 · Pulmonx Stock Performance. Shares of Pulmonx stock opened at $10.85 on Tuesday. The firm has a market capitalization of $415.64 million, a P/E ratio of -6.70 and a beta of 0.48. Pulmonx Co. has a ... Pulmonx Corporation (Nasdaq: LUNG) (' Pulmonx '), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr Endobronchial Valve for treating severe COPD/emphysema patients following a positive …But others have seen delays in their business, and COVID-19 has hurt these stocks. Some of these companies are real bargains now. Three Fool.com contributors like pulmonary specialist Pulmonx ...Pulmonx Corp’s Stock Price as of Market Close. As of March 10, 2023, 4:00 PM CST, Pulmonx Corp’s stock price was $10.74. Pulmonx Corp is down 5.79% from its previous closing price of $11.40. During the last market session, Pulmonx Corp’s stock traded between $11.23 and $11.93. Currently, there are 37.38 million shares of Pulmonx Corp ...

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease ...Geoffrey Beran Rose, Insider at Pulmonx (NASDAQ:LUNG), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange ...Nov 29, 2023 · 7 equities research analysts have issued twelve-month price targets for Pulmonx's shares. Their LUNG share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.29 in the next year. This suggests a possible upside of 20.2% from the stock's current price. Pulmonx Corporation Common Stock (LUNG) Stock Price, Quote, News & History | Nasdaq MY QUOTES: LUNG Edit my quotes Pulmonx Corporation Common Stock (LUNG) 0 Add to Watchlist Add...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Pulmonx continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based ...

The all-time high Pulmonx stock closing price was 69.02 on December 31, 2020 . The Pulmonx 52-week high stock price is 45.49 , which is 268.6% above the current share price. The Pulmonx 52-week low stock price is 12.23 , which is 0.9% below the current share price. The average Pulmonx stock price for the last 52 weeks is 22.86 . For more ...

Pulmonx Corporation (LUNG.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Pulmonx Corporation | Nasdaq: LUNG | Nasdaq Nov 13, 2023 · Pulmonx Corp Stock Price History. Pulmonx Corp’s price is currently up 13.99% so far this month. During the month of November, Pulmonx Corp’s stock price has reached a high of $10.10 and a low of $8.60. Over the last year, Pulmonx Corp has hit prices as high as $14.28 and as low as $5.13. Year to date, Pulmonx Corp’s stock is down 68.76%. The stock opened at $40 on day 1, and soon galloped to almost $70 a share (Figure 5). However, Pulmonx, along with other speculative equities, soon cooled off. From the peak in January 2021, LUNG ...REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease ...10 stocks we like better than Pulmonx Corporation When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool ...Get the latest Pulmonx Corp (LUNG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …

But others have seen delays in their business, and COVID-19 has hurt these stocks. Some of these companies are real bargains now. Three Fool.com contributors like pulmonary specialist Pulmonx ...

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases.

Pulmonx started at buy with $49 stock price target at Canaccord Genuity MarketWatch. 09:51 AM ET. Pulmonx started at buy with $50 stock price target at Stifel Nicolaus MarketWatch. 07:12 AM ET. Thursday, Oct 01, 2020. Pulmonx shares soar 118% in trading debut MarketWatch. 11:36 AM ET.LUNG Stock 12 Months Forecast. $16.20. (61.35% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Pulmonx in the last 3 months. The average price target is $16.20 with a high forecast of $18.00 and a low forecast of $15.00. The average price target represents a 61.35% change from the last price of $10.04.Pulmonx Corp Stock Price History. Pulmonx Corp’s price is currently up 13.99% so far this month. During the month of November, Pulmonx Corp’s stock price has reached a high of $10.10 and a low of $8.60. Over the last year, Pulmonx Corp has hit prices as high as $14.28 and as low as $5.13. Year to date, Pulmonx Corp’s stock is down 68.76%.May. 09. CI. Piper Sandler Adjusts Pulmonx's Price Target top $15 From $13, Keeps Overweight Rating. May. 03. MT. Morgan Stanley Adjusts Pulmonx's Price Target to $14 From $11, Keeps Equalweight Rating. May. 03. MT. Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $14.5M, vs. Street Est of $13.5M.Nov 24, 2023 · Craig Hallum started coverage on shares of Pulmonx in a report on Tuesday, September 5th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Piper Sandler lowered their target price on shares of Pulmonx from $17.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, October 31st. Get ... Mar 10, 2023 · Pulmonx Corp’s Stock Price as of Market Close. As of March 10, 2023, 4:00 PM CST, Pulmonx Corp’s stock price was $10.74. Pulmonx Corp is down 5.79% from its previous closing price of $11.40. During the last market session, Pulmonx Corp’s stock traded between $11.23 and $11.93. Currently, there are 37.38 million shares of Pulmonx Corp ... Get the latest Pulmonx Corp (4NI.MU) stock news and headlines to help you in your trading and investment decisions.Pulmonx Corporation 2020 Employee Stock Purchase Plan (Full titles of the plans) Glendon E. French. Chief Executive Officer. Pulmonx Corporation. 700 Chesapeake Drive. Redwood City, California 94063. 1-650-364-0400 (Name, address and telephone number, including area code, of agent for service) Copies to:Nov 8, 2023 · Verdict: Pulmonx Corporation lost a $1.59 a share on just over $53.6 million of revenue in FY2022. The current analyst firm consensus has losses increasing to $1.71 a share in FY2023 even as sales ... But others have seen delays in their business, and COVID-19 has hurt these stocks. Some of these companies are real bargains now. Three Fool.com contributors like pulmonary specialist Pulmonx ...7 equities research analysts have issued twelve-month price targets for Pulmonx's shares. Their LUNG share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.29 in the next year. This suggests a possible upside of 20.2% from the stock's current price.

Stocks United States LUNG Overview Stock Screener Earnings Calendar Sectors Nasdaq | LUNG U.S.: Nasdaq Pulmonx Corp. Watch list NEW Set a price target alert Open Last Updated: Nov 1, 2023 2:59... Pulmonx Corp’s Stock Price as of Market Close. As of May 31, 2023, 4:00 PM CST, Pulmonx Corp’s stock price was $12.01. Pulmonx Corp is up 4.34% from its previous closing price of $11.51. During the last market session, Pulmonx Corp’s stock traded between $11.46 and $11.70. Currently, there are 37.57 million shares of Pulmonx Corp stock ...Nov 27, 2023 · On Friday, September 22nd, Geoffrey Beran Rose sold 1,184 shares of Pulmonx stock. The stock was sold at an average price of $10.51, for a total transaction of $12,443.84. Glendon E. French III Sells 6,533 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock. Pulmonx Co. (NASDAQ:LUNG – Get Rating) CEO Glendon E. French III sold 6,533 shares of Pulmonx stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $11.48, ...Instagram:https://instagram. voya best buyamd buy or sellmanchester united sharebuy cricket phone Pulmonx now expects total operating expenses for the full year 2021 to fall within the range of $83 to $85 million inclusive of stock-based compensation. Webcast and Conference Call Details Pulmonx will host a conference call today, November 2, 2021, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2021 financial results. options prop firmis google a good stock to buy 8.99. +0.30. +3.45%. Get Pulmonx Corp (LUNG:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. has the stock market bottomed out Glendon E. French, III has not been actively trading shares of Pulmonx within the last three months. Most recently, Glendon E. French III sold 6,527 shares of the business's stock in a transaction on Friday, September 1st. The shares were sold at an average price of $10.01, for a transaction totalling $65,335.27.3.57%. Percent of Float. 4.00%. Overview. Complete Pulmonx Corp. stock information by Barron's. View real-time LUNG stock price and news, along with industry-best analysis.